Enterprise Value
167M
Cash
56.14M
Avg Qtr Burn
-22.03M
Short % of Float
1.76%
Insider Ownership
9.68%
Institutional Own.
22.70%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ROLVEDON™ (ex ROLONTIS™) (eflapegrastim) Details Blood disorder, Genetic disorder, Achromatopsia | Approved Update | |
Poziotinib Details Non-small cell lung carcinoma, Cancer | Failed Discontinued |